For years, Moderna was a one-hit wonder, a company that bet everything on mRNA, struck gold with a COVID vaccine and then watched its stock crater as the pandemic faded. Now, the company may have found a way to fight skin cancer. An experimental mRNA-based vaccine succeeded in preventing melanoma from returning in high-risk patients, sending drug industry stocks soaring. WSJ’s Xavier Martinez traces Moderna’s wild ride from scrappy startup to the frontier of can treatment. Ryan Knutson hosts.
Further Listening:
- The FDA Commissioner on Vaccines and Public Trust
- The Creator of the Record-Setting Covid Vaccine
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
